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Background: The global burden from cancer is rising, especially as low-income countries like Bangladesh observe
rapid aging. So far, there are no comprehensive descriptions reporting diagnosed cancer group that include
hematological malignancies in Bangladesh.
Methods: This was a multi-center hospital-based retrospective descriptive study of over 5000 confirmed
hematological cancer cases in between January 2008 to December 2012. Morphological typing was carried out
using the “French American British” classification system.
Results: A total of 5013 patients aged between 2 to 90 years had been diagnosed with malignant hematological
disorders. A 69.2% were males (n = 3468) and 30.8% females (n = 1545), with a male to female ratio of 2.2:1. The
overall median age at diagnosis was 42 years. Acute myeloid leukemia was most frequent (28.3%) with a median
age of 35 years, followed by chronic myeloid leukemia with 18.2% (median age 40 years), non-Hodgkin lymphoma
(16.9%; median age 48 years), acute lymphoblastic leukemia (14.1%; median age 27 years), multiple myeloma
(10.5%; median age 55 years), myelodysplastic syndromes (4.5%; median age 57 years) and Hodgkin’s lymphoma
(3.9%; median age 36 years). The least common was chronic lymphocytic leukemia (3.7%; median age 60 years).
Below the age of 20 years, acute lymphoblastic leukemia was predominant (37.3%), followed by acute myeloid
leukemia (34%). Chronic lymphocytic leukemia and multiple myeloma had mostly occurred among older patients,
aged 50-over.
Conclusions: For the first time, our study presents the pattern and distribution of diagnosed hematological cancers
in Bangladesh. It shows differences in population distributions as compared to other settings with possibly a lower
presence of non-Hodgkin lymphoma. There might be under-reporting of affected women. Further studies are
necessary on the epidemiology, genetics and potential environmental risk factors within this rapidly aging country.
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Once considered a problem exclusive to Western coun-
tries, cancer is becoming a leading cause of death and
disability in low-income countries. In 2012 more than
57% of the 14.1 million cancer cases and 65% of the 8.2
million cancer deaths occurred in these settings [1]. Even
if current global cancer rates would remain unchanged,
low- and lower-middle income countries would bear the
burden of more than two thirds of the projected 21.7%
million new cancer cases and 13 million cancer deaths by
2030 [1]. Despite current or future efforts, the challenges
of tackling cancer are enormous, since the occurrence of
cancer in these settings will continue to rise due to
increasing in lifespans through better control of commu-
nicable diseases [2].
Bangladesh shows major advances in relation to the
management of infectious diseases as recently highlighted
in Lancet [3], the chronic diseases in particular cancers are
less prioritized [4]. The status of cancer in this country is
largely unknown, as there is no population-based cancer
registry nor a national cancer registry of any other kind.
According to WHO, Bangladesh is experiencing increas-
ing cancer burden with estimated 122,715 new cancer
cases in 2012 [1] The number of new cases is projected
to increase approximately by 77% in 2030. These WHO
estimates may not reflect the real cancer status, as the
estimates were extrapolated based on the incidence and
mortality rates from regional data (India) and a single
hospital [1]. The figures are likely to underestimated as
many cases go unreported due to lack of awareness, edu-
cation, misconceptions, and poverty among populations,
in addition due to poor health systems and poor govern-
ance [5]. Moreover, overall cancer care and management
systems are below international standard due to the high
treatment costs, the lack of oncologists and insufficient
infrastructure.
Hematological malignancies (HM) comprise approxi-
mately 6.5% of all cancer incidences worldwide in 2012
[1]. Although prevalence of these malignancies are much
lower in Asia and Africa then in Western countries, the
incidence of these malignancies is drastically increasing
in low-income settings, while these increasing trends are
not observed in Western countries [6-8]. WHO predicts
that the number of blood-related cancer cases would
increase about 48% in less developed countries by 2030
as compared to 2012 [1].
HM are primary cancers originating from cells of the
bone marrow and lymphatic system [9] and there are
three main categories including forms of leukemia,
lymphoma, and multiple myeloma (MM). Other in-
cludes myelodysplastic syndrome (MDS), polycythaemia
vera, and primary myelofibrosis. The four common
types of leukemia are: acute myeloid leukemia (AML),
acute lymphoblastic leukemia (ALL), chronic myeloidleukemia (CML), chronic lymphocytic leukemia (CLL).
The two main types of lymphoma are: non-Hodgkin
lymphoma (NHL) and Hodgkin’s lymphoma (HL). The
causes of hematological malignancies remain unclear, but
these are believed to be linked with environmental expos-
ure of chemicals (such as pesticides, benzene, smoking
etc.), as well as ionizing radiation and infectious agents.
The incidence of HM varies with geography, age and race/
ethnicity, suggesting different etiological factors may con-
tribute for the development of these malignancies [10,11].
Information pertaining to the epidemiological aspects
of HM in South Asian population is limited [12]. In case
of Bangladesh, there is no published report on HM preva-
lence and treatment. An understanding of the epidemio-
logical aspects of HM would surely contribute to identify
the risk factors in our environmental background and
would provide epidemiological basis for devising the can-
cer care management and preventive strategies of these
malignancies. In the present retrospective study, we report
for the first time the overall pattern and age distribution
of hematological malignancies in Bangladesh.
Methods
Bangladesh has one state-run specialized cancer hospital,
fourteen oncology units of public medical teaching hos-
pitals and few private clinics and hospitals available for
the management of all cancer patients. While over 70%
of the population live in rural areas, most of the tertiary
health care facilities for cancer treatment are centred in
the capital city, Dhaka [13]. Therefore, patients seeking
for cancer treatment travel to Dhaka. In our retrospective
analysis, the study population consists of all patients with
hematological malignancies diagnosed at the tertiary
and specialized hospitals in Dhaka from January 2008 to
December 2012. Not all hospitals provided data over
the above-mentioned time period since some of them
had not started to handle HM cases. Data extraction oc-
curred for those hospitals that have been capable of mak-
ing a definite diagnosis of hematological malignancies.
Two hospitals outside of Dhaka city - Chittagong Medical
College and Hospital and Rajshahi Medical College
Hospital were included (Table 1).
Our study is based on the recorded diagnoses of HM
in the various participating centres. The source of the
information included bone marrow morphology data-
bases from the hematopathology laboratories as well as
inpatient and outpatient case registers maintained at
the participating hospitals. The participating hospital
mostly provided both pathological diagnoses and clinical
management information. The exception was BIRDEM
General Hospital where service is limited to diagnostic
services. Diagnoses were carried out on the basis of clin-
ical features, blood counts, peripheral blood films and
bone marrow morphology including cytochemical staining
Table 1 Case distribution by institution and year
Institution Duration (year) No of cases (n) Existing facilities for HM diagnosis
CMCH 2011-12 153 Morphological
CMH 2012 75 Morphological, cytochemistry, karyotyping, immunocytochemistry
RMCH 2012 148 Morphological
Green View Hospital 2012 264 Morphological, cytochemistry
Delta Hospital 2008-12 146 Morphological, cytochemistry, immunocytochemistry
Square Hospital Ltd. 2008-12 180 Morphological, immunocytochemistry
NICRH 2010-12 781 Morphological
BIRDEM 2008-12 208 Morphological, karyotyping
BSMMU 2008-12 1907 Morphological, cytochemistry, immunocytochemistry
DMCH 2008-12 1151 Morphological
Total 2008-12 5013
Table 2 Distribution pattern, median age at diagnosis
and male–female ratio of hematological malignancies in
Bangladesh






AML 1417 28.3 35 1.9
CML 912 18.2 40 2.1
ALL 706 14.1 27 2.1
CLL 183 3.7 60 2.9
NHL 846 16.9 48 3.6
HL 196 3.9 36 3.4
MM 528 10.5 55 2.1
MDS 225 4.5 57 1.9
Total 5013 100 42 2.2
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available for the diagnosis of HM at various participat-
ing centres are shown in Table 1. Morphological typing
of malignancies was carried out according to “French
American British (FAB)” classification system. Although
WHO classification (2008) for haematological malig-
nancies is based mostly on immunophenotype and mo-
lecular markers, we had to stick to FAB classification
because we had limited facilities for immunophenotyping
or cytogenetic studies. Our diagnoses were supplemented
by criteria from the 2008 WHO classification whenever
facilities were available to fulfil the criteria as shown in
Table 1.
As there is no proper and effective hospital record keep-
ing system in Bangladesh, there are always possibilities that
the same patient might visited multiple times in the same
hospitals and/or different hospitals. These would eventu-
ally undermine the actual diagnosed cases of HM. To
eliminate these possibilities, raw data were painstakingly
analyzed to clean up such duplicated, re-enrolled cases. In-
dividual co-authors initially sorted and cleaned up the data
of their own hospitals. Later, a team of investigators in-
cluding MSH, MSI and TAS carefully cross-checked all
data from participating centres for potential duplicates
or re-enrolled cases depending on various parameters
including name of the patient, age, year of diagnosis and
the name of the hospital attended. The initial dataset
contained 5338 cases. At the end, 5013 diagnosed cases
were analyzed in our study after removing all duplicated
or re-enrolled cases (6% of all cases). It was not possible
to get information on the cancer-associated deaths due
to lack of proper record keeping system. Final data
representing individual cases were analyzed by SPSS
version 17 statistical software. The study protocol was
ethically approved by the Ethical Review Committee of
Diabetic Association of Bangladesh under the official
memo no. BADAS-ERC/EC/13/0081.Results
A total of 5013 diagnosed hematological malignancy-
related cases extracted from ten different tertiary hospi-
tals were retrospectively analysed in this study. Of these,
patients aged between 2 to 90 years, 3468 were males
(69.2%) and 1545 females (30.8%), with a male to female
ratio of 2.2:1 (Table 2). Male-biased prevalence of HM
was statistically significant (χ2 = 54.28, P = 0.001). Among
all hematological malignancies cases, 6.7% (n = 338) were
children aged under 20 years old (Table 3). The com-
bined median age at diagnosis for all hematological ma-
lignancies was 42 years.
AML was the most frequent HM (28.3%) in Bangladesh
with a median age of 35 years. This was followed by CML
(18.2%, median age 40 years), NHL (16.9%, median age
48 years), ALL (14.1%, median age 27 years), MM (10.5%,
median age 55 years), MDS (4.5%, median age 57 years)
and HL (3.9%, median age 36 years). The least common
HM was CLL (3.7%, median age median age 60 years)
[Table 2].
Table 3 Age-group specific distribution of hematological malignancies in Bangladesh
Age group AML CML ALL CLL NHL HL MM MDS Total cases Age-specific
% (n) % (n) % (n) % (n) % (n) % (n) % (n) % (n) n %
Under 20 8.1 (115) 4.1 (44) 17.8 (126) 1.6 (3) 2.1 (18) 14.3 (28) 0.2 (1) 1.3 (3) 338 6.7
20-29 24.5 (347) 21.3 (194) 38.8 (274) 1.6 (3) 17.6 (149) 21.9 (43) 1.1 (6) 6.2 (14) 1030 20.5
30-39 22 (312) 23.8 (217) 17 (120) 4.4 (8) 12.5 (106) 15.8 (31) 2.8 (15) 5.8 (13) 822 16.4
40-49 18.1 (256) 21.1 (192) 10.6 (75) 9.3 (17) 20.6 (174) 25 (49) 19.1 (101) 9.8 (22) 886 17.7
50-59 14.1 (200) 16.4 (150) 6.9 (49) 20.8 (38) 24.1 (204) 15.8 (31) 36.6 (193) 29.3 (66) 931 18.6
60-69 8.1 (115) 10.3 (94) 5.8 (41) 28.4 (52) 16.4 (139) 4.1 (8) 24.8 (131) 25.8 (58) 638 12.7
70+ 5.1 (72) 2.3 (21) 3 (21) 33.9 (62) 6.6 (56) 3.1 (6) 15.3 (81) 21.8 (49) 368 7.3
Total cases 1417 912 706 183 846 196 528 225 5013 100
Table 4 Median age at diagnosis of hematological
malignancies in Bangladesh as compared to India and US
HM Median age at diagnosis (year)
Bangladesh India US [23]
AML 35 30 67
CML 40 38-40 64
ALL 27 23 14
CLL 60 60 71
NHL 48 49.5* 66
HL 36 31.9* 38
MM 55 55-56 69
MDS 57 46.1* 60-70
All types 42 ~ 40** 65-70
*Mean age.
**Estimated, specific reference is not available.
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the overall and individual cancer cases. No significant dif-
ference was observed in the median age of presentation
(male 42 years; female 41 years) for both sexes except for
ALL (male 25 years, female 30 years), HL (male 40 years,
female 28 years), CLL (male 61 years, female 50 years) and
MDS (male 59.5 years and female 55 years).
Age-group specific distribution showed that three
types of HM including AML (64.6%), CML (66.2%), ALL
(66.4%), and HL (62.7%) were predominantly observed in
the young adults aged 20-49 years (Table 3). Interestingly,
four other HM were mostly occurred among older pa-
tients aged 50-over 70 years. These include CLL (83.1%),
MM (76.7%) and MDS (76.9%). On the other hand, NHL
was almost evenly distributed among 20–49 years (50.7%)
and 50-over 70 years (49.3%) age group (Table 3).
Among 338 childhood HM cases analyzed in our
study, 257 cases were in 15–19 year age group, while 81
cases were in 0–14 year age group. In children younger
than 20 years, ALL (37.3%) was the predominant type of
HM, followed by AML (34%), CML (13%), HL (8.3%)
and NHL (5.3%) [Table 3].
Discussion
To our knowledge, this is the first comprehensive re-
port on the burden of hematological malignancies in
Bangladesh. In contrast to the WHO estimates, our
multi-centred hospital-based data present a different pic-
ture: the leukemias constituted approximately two thirds
of (64.3%) all HM cases, while NHL accounted for 16.9%,
followed by MM (10.5%) and HL (3.9%) [Table 2]. A simi-
lar pattern of leukemias (Age-standardized incidence rate
or ASR per 100,000 is 3.3), NHL (ASR per 100,000 is 3),
and multiple myeloma is observed in India. The WHO
prediction, the commonest type of HM was NHL (ASR is
1.9 per 100,000 persons), which was followed by leukemias
(ASR 1.7 per 100,000 persons), HL and multiple myeloma
[1]. In Pakistan, NHL is the most prevalent type of HM
[1]. In US, NHL is the commonest cancer among HM,
which is 1.5 times that of all leukemias [14]. In contrast,all leukemia cases were over three times higher as com-
pared to NHL cases in Bangladesh. In other Asian
countries including Japan, Korea and Singapore, NHL
is the most frequent hematological malignancies [1,7].
In our study, this unexpected discrepancy might be due
to lack of proper referral system in some participating
centres. Although lymphoma is a haematological dis-
order, a small number of patients might have been ad-
mitted to the medical oncology department. Moreover,
year-specific data was not available for four of the par-
ticipating centres (Table 1). Yet, our hospital-based study
represents the overall current country picture on HM.
Additional population-based studies are warranted to
reveal the true incidence of HM.
Unlike Western countries, the hematological malignan-
cies in Bangladesh seem to afflict younger population as is
indicated by the overall median age at diagnosis was
42 years. Perhaps the true median age may be even lower,
given the under-representation of children in this study.
Acute leukemias (AML and ALL), CML and lymphoma
(NHL and HL) were found to occur in relatively young
adults with a median age ranging from 27 to 48 years
(Table 4). On the other hand, MM, CLL and MDS were
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at diagnosis was 55 to 60 years). It is generally argued
that young age phenomenon of cancers might be due to
the lower life expectancy and younger population struc-
ture of a respective country [12,15,16]. In Bangladesh,
33% of the population is under 15 years old and the me-
dian age of the entire population is 23.4 years. Another
often cited reason is related to the underreporting cases
of older individuals possibly because of several socio-
economic and cultural reasons. However, the lower life
expectancy explanation is doubtful as in economically
developed Singapore, Hong Kong, South Korea, Taiwan
and Japan - with much higher life expectancies similar
to those seen in Western countries - are also affected by
CML [17], NHL [18] and MDS [19] at relatively young
ages. The reasons behind this phenomenon are unclear.
However, it is likely that the multiple factors including
genetic, infections and other environmental factors
might play crucial role in this young age phenomenon
in Asia. Moreover, an analysis with migrant Bangladesh/
Indian living in economically developed regions with
different life expectancy may help to understand this
issue further.
Our retrospective analysis included 6.7% childhood
(under 20 years) HM cases (n = 338), of which approxi-
mately 76% cases comprised of adolescent (15–19 years
age group) cancer patients. It is important to mention
that childhood cases were under represented in the
present study as the information was obtained from the
hematology department of some of the major participating
centres which usually manage childhood (0–14 years)
cases in separate facilities. Despite this limitation, we
can present an overview of children hematological ma-
lignancies in Bangladesh. Leukemias were found to be
the most common blood associated cancers, constitut-
ing of 92.6% of all children HM cases (Table 3). Among
these leukemia patients, ALL is the most frequent cancer
accounting for 37.3% (n = 126) followed by AML (34%,
n = 115) and CML (13%, n = 44). Lymphoma accounted
for 13.6% (HL-8.3% and NHL-5.3%) of all children cases.
Like Western countries and Bangladesh, the leukemias
were the most prevalent childhood cancers in India with a
relative proportion ranging from 25-40% of all childhood
cancers. Approximately 60 to 85% of all reported leuke-
mias was ALL [20]. Further extensive study is necessary to
understand the pattern and distribution of HM among
children in the country.
Studies all over the world have revealed that hematologi-
cal malignancies is gender-skewed, often affecting men
more than women. We also found that men were more in-
volved than women, with an overall male to female ratio of
2.2. For lymphoma, this ratio (~3.4) seems to be much
higher than normal trend. Probably, female cases were
underreported considering the socioeconomic status of thefamilies and in low-resource settings usually men often
get priority while seeking medical attention. The higher
prevalence of HM in males might be the result of in-
creased exposure to environmental and occupational
risk factors, smoking, alcohol consumption as well as
different hormonal and genetic background of males
and females [10,21-23].
Acute leukemias including AML and ALL are the
most prevalent HM affecting Bangladeshi population,
accounting for 42.4% (n = 5013) of all HM cases, while
these two constituted 66% (n = 3218) of leukemia cases
(Table 2). The frequency of AML is two times higher
than that of ALL in Bangladesh. The incidence of AML
is relatively common in North America, Europe, and
Oceania, while adult AML is rare in Asia and Latin
America [24]. AML generally affects older individuals
with a median age at presentation of around 65 years in
Western countries [11] and it accounts for ~ 29% of all
leukemias in adults in US. Our study showed that acute
leukemias tend to affect relatively young adults aged
20–49 years (66.4% cases) [Table 3]. The median age at
onset for AML (35 years) in Bangladesh is higher than
in India (30 years) [12]. Apart from lower life expectancy
prevailing in the Indian subcontinent, it is likely that eld-
erly patients may not be reporting to the hospitals because
of relatively rapid progression of AML. ALL occurs in
people of all ages but it exhibits bimodal age-specific curve
with peaks in youngest (<20 years) and oldest ages
(>50 years). In our study we observed that more than 55%
of the ALL occurs in young adults (20–40 years) with a
median of 27 years (Table 3). In US, the overall median
age for ALL is only 14 years, since approximately 60% of
the cases occur in children under 20 years old [25]. In case
of adult, the median age was 38 years [26].
Chronic leukemias constituted 21.9% of all HM and
34% of leukemias in Bangladesh. CML is the second
most common type (18.2%, n = 912), while CLL is the least
frequent (3.7%, n = 183) HM (Table 2). The frequency of
CML is five times higher than CLL. The pattern of CML
occurrence is different in India and Africa where it is
the most common form of leukemia [12,27]. In Sudan,
the incidence of CML is very high, being the predomin-
ant cancer in men in last 25 years [28]. CLL is a rare
hematological malignancy in Asia while this is the com-
monest form of leukemia affecting elderly in Western
countries with a median age of 70 years [11] . In US, for
instance, CLL constitutes about ~34% of all leukemia
[14]. In Bangladesh and India, CLL is found to occur
mainly in adults (median age ~60 years) [29]. The lower
frequency of CLL in Bangladesh and its neighbouring
countries may not be associated with lower life expect-
ancy since the incidence of CLL in Japan is at least 4 to
5 times lower than Western countries; despite Japanese
have the highest life expectancy in the world [30]. It is
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portant role in its development [11,31].
Malignant lymphoma constituted 20.8% of all HMs in
our study (Table 2). Out of 1052 lymphoma cases, NHL
accounted for 80.4% while 19.6% was for HL. The fre-
quency of NHL and HL observed in the present study
was almost similar to the earlier report from India [32].
NHL is one of the commonest cancers in developed
countries, but the incidence is relatively lower in Asia
[18]. This is the most frequent HM of many Asian [1,18]
and African countries [33]. In Bangladesh, it constituted
16.9% of all HM with a median age of 48 years. On the
other hand, HL is the most common cancer of young
adults in developed countries. The age distribution of
HL is bimodal, the first being young adults (age 15–35
years) and the second being those in older individuals
over 55 years old. In our study, 62.7% of all HL cases oc-
curred among young adults (<50 years) with a median of
36 years. The similar frequency of HL pattern was also
observed in India where mean age of diagnosis was
31.9 years [32].
In our study, nearly 76.7% of the MM patients aged
over 50 years. This accounted for 10.5% of all HM. In
Western countries, the median age at diagnosis is 65–70
years, which is significantly higher as compared to Asian
countries like India, Japan and China [34]. The median
age at onset in Bangladesh is 55 years, which similar to
that in India (55–56 years). The incidence varies among
different races or geographic location. For instance, the
higher incidence has been reported for African Americans
as compared to Caucasians [35].
Myelodysplastic syndromes (MDS) are relatively a con-
dition affecting elderly. It can transform to AML. The in-
cidence of MDS is unclear worldwide because of historical
lack of population-based registration. In Bangladesh, MDS
constituted approximately 4.5% of HM and 76.9% (n = 225)
of the patients were over 50 years old with a median age of
57 years, which is similar to that reported in Japan [19]. In
case of India, the MDS patients were much younger with a
mean age of 46.1 years [36], while Western countries have
median age ranges from 60–70 years [37].
Large sample size (over 5000 diagnosed cases) is the
strength of our study. However, in our retrospective
study, we could not provide any information on the
mortality and survivorship of HM, since there is no
proper follow-up system to track terminally-ill patients
in Bangladeshi hospitals. Detailed clinical data were also
not available because of incomplete record keeping sys-
tem. Like other low-income countries, many of these
limitations are intrinsic to Bangladesh health system.
Time-trend analysis was not also possible due to lack of
homogeneity of data obtained from different hospitals,
which has been described in the method section and
elsewhere.Conclusion
This study of a large number of HM patients is a very
first step in understanding the patterns and distribution
of HM in Bangladesh. Further investigations are necessary
to understand the epidemiology, potential risk factors,
biology and genetics of hematological malignancies in
this country in rapid transition.
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